Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers.

× No keyword cloud information.

11 in total

1. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors: E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal: N Engl J Med Date: 2001-09-20 Impact factor: 91.245

2. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors: S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal: N Engl J Med Date: 2000-01-20 Impact factor: 91.245

3. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

Authors: J N Cohn; G Tognoni
Journal: N Engl J Med Date: 2001-12-06 Impact factor: 91.245

4. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

Authors: B Pitt; P A Poole-Wilson; R Segal; F A Martinez; K Dickstein; A J Camm; M A Konstam; G Riegger; G H Klinger; J Neaton; D Sharma; B Thiyagarajan
Journal: Lancet Date: 2000-05-06 Impact factor: 79.321

5. Additive effects of losartan and enalapril on blood pressure and plasma active renin.

Authors: M Azizi; T T Guyene; G Chatellier; M Wargon; J Ménard
Journal: Hypertension Date: 1997-02 Impact factor: 10.190

6. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators.

Authors: M R Weir; M A Weber; J M Neutel; J Vendetti; E L Michelson; R Y Wang
Journal: Am J Hypertens Date: 2001-06 Impact factor: 2.689

7. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors: H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal: N Engl J Med Date: 2001-09-20 Impact factor: 91.245

8. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors: B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal: N Engl J Med Date: 2001-09-20 Impact factor: 91.245

9. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors: Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal: Lancet Date: 2002-03-23 Impact factor: 79.321

Review 10. Angiotensin-II receptor antagonists: a new class of antihypertensive agents.

Authors: M R Weir
Journal: Am Fam Physician Date: 1996-02-01 Impact factor: 3.292